KRAS and cancer: Importantly, our screening strategy also identified previously undescribed drug interaction patterns and several novel combinations with high efficacy against KRAS-mutant cancers, for example, the combined inhibition of PLK1 and ROCK (CI=0.33 at median effective dose).